PolyPeptide Group AG, a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that its shareholders approved all proposals put forward by the board of directors at an extraordinary general meeting held on October 26, 2026. The approvals mark a critical step in the proposed acquisition of PolyPeptide by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., which has launched a public tender offer for all publicly held registered shares of PolyPeptide.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang, and Joonkyung Seong as members of the board for a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected chair of the board, while Cheol Woo Ryu and Seungho Ryu were elected to the Remuneration and Nomination Committee. These elections are subject to and effective as of the settlement of the tender offer by Samsung Peptide AG.
The shareholders also resolved to remove the transfer restrictions and voting limitations from PolyPeptide’s articles of association, subject to the satisfaction or waiver of all offer conditions set forth in the offer prospectus of Samsung Peptide AG dated August 31, 2026, except for the condition in section B.7.1(e). This change eliminates key barriers to the acquisition and allows for a smoother transfer of shares.
The implications of these decisions are significant. The board reconstitution and the removal of governance obstacles effectively clear the path for Samsung Biologics to complete its takeover. The new board, composed of individuals with ties to the acquirer, will oversee PolyPeptide during the transition. For the broader peptide CDMO market, the acquisition underscores the strategic value of peptide manufacturing capabilities, particularly given PolyPeptide’s exposure to metabolic diseases and GLP-1 therapies. The deal could reshape competitive dynamics in the rapidly growing market for peptide-based active pharmaceutical ingredients.
PolyPeptide operates a global network of six GMP-certified facilities across Europe, the U.S., and India, dating back to 1952. The company’s shares are listed on the SIX Swiss Exchange. For more information, visit polypeptide.com. The company also maintains a presence on LinkedIn. The original release is available on www.newmediawire.com.
